What is CBG (Cannabigerol)

With CBD becoming ubiquitous these days, it's important to know that it is only one of the hundreds of phytocannabinoids found in the hemp plant. In this blog post, we want to shed light on the lesser-known cannabinoid, Cannabigerol or CBG, which has proven to offer a significant amount of therapeutic potential.

CBG, also known as the "mother cannabinoid," is the first cannabinoid present in the hemp plant during its growth. As the plant matures, CBG gives rise to other primary cannabinoids such as CBD and THC (<0.3%). In The Science Behind CBD, we discuss how cannabinoids interact with our endocannabinoid system to bring our bodies back into balance or homeostasis.

What does CBG do?

Because our endocannabinoid system acts as our body's control center, supplementing with cannabinoids from organic plant sources can help regulate hormones, mood disorders, blood sugar levels, alertness, sleep, pain, and functions associated with our immune system.

The hemp industry is rapidly evolving, with breeders, growers, and scientists now focusing on the therapeutic properties of specific cannabinoids like CBG. Research has shown that CBG has numerous therapeutic properties, including anti-inflammatory properties that can offer relief for many people. Since most ailments are associated with inflammation, CBG could be the answer we've been waiting for. By reducing inflammation, CBG may also help reduce overall pain levels and other unwanted symptoms. Additionally, CBG may help relieve allergies, slow fungal growth, reduce abnormal cell growth, and slow the progression of neurodegenerative diseases such as Alzheimer's, Huntington's, Parkinson's, and Dementia.

At Root Therapeutics, we believe that CBG is the unsung hero of the hemp plant, with immense therapeutic potential. If you're interested in incorporating CBG into your daily regimen, check out our favorite

Sources:

Carrillo-Salinas FJ, Navarrete C, Mecha M, et al. A cannabigerol derivative suppresses immune responses and protects mice from experimental autoimmune encephalomyelitis. PLoS One. 2014;9(4):e94733. Published 2014 Apr 11. doi:10.1371/journal.pone.0094733

Granja A. G., Carrillo-Salinas F., Pagani A., Gómez-Cañas M., Negri R., Navarrete C., et al. (2012). A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis. J. Neuroimmune Pharmacol. 7 1002–1016. 10.1007/s11481-012-9399-3

Navarro G., Borroto-Escuela D., Angelats E., Etayo Í., Reyes-Resina I., Pulido-Salgado M., et al. (2018a). Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB1 and CB2 receptors and relevance for Alzheimer’s disease and levodopa-induced dyskinesia. Brain Behav. Immun. 67 139–151. 10.1016/j.bbi.2017.08.015

Vučković S, Srebro D, Vujović KS, Vučetić Č, Prostran M. Cannabinoids and Pain: New Insights From Old Molecules. Front Pharmacol. 2018;9:1259. Published 2018 Nov 13. doi:10.3389/fphar.2018.01259